Brain Metastases, Brain Metastases, Adult, Metastatic Brain Cancer, Metastatic Brain Tumor
Conditions
Keywords
Brain Metastases, Healthy Volunteers, metastatic brain tumor, metastatic brain cancer, Brain Metastases, Adult, MRI, untreated brain metastasis, CEST-MRF, chemical exchange saturation transfer magnetic resonance fingerprinting, 22-191, Memorial Sloan Kettering Cancer Center
Brief summary
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Interventions
DIAGNOSTIC_TESTCEST-MRF
CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * No known cancer diagnosis Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) * Planned SRS treatment
Exclusion criteria
Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motion | Up to 3 years | Develop a rapid and robust 3D CEST-MRF pulse sequence for clinical scanners using our preclinical CEST-MRF pulse sequence as a basis by evaluating the changes of the 6 CEST-MRF parameters with and without motion. These parameters include the water T1 and T2 relaxation (T1w,T2w), amide exchange rate (ksw) and volume fraction (fs) and the semi-solid exchange rate (kssw) and volume fraction (fss). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Create CEST-MRF parameter maps | Up to 3 years | Develop an MRI physics-guided artificial intelligence approach to improve acquisition and reconstruction of multiparametric data |
| Measure longitudinal changes in CEST-MRF after SRS | Up to 3 years | Evaluate CEST-MRF changes before and after radiation therapy to assess potential role as predictive imaging biomarker for brain metastases |
Countries
United States
Contacts
CONTACTOuri Cohen, PhD
CONTACTNelson Moss, MD
PRINCIPAL_INVESTIGATOROuri Cohen, PhD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed